Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Natl Cancer Inst
    November 2024
  1. HAMMARLUND N, Holt SK, Etzioni R, Morehead D, et al
    The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
    J Natl Cancer Inst. 2024 Nov 20:djae302. doi: 10.1093.
    >> Share

  2. ZHAO Y, Gulati R, Yang Z, Newcomb L, et al
    Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
    J Natl Cancer Inst. 2024 Nov 20:djae296. doi: 10.1093.
    >> Share

    October 2024
  3. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
    When is prostate cancer really cancer?
    J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
    >> Share

  4. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    >> Share

  5. LIU S, Rivero SL, Zhang B, Shen K, et al
    BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression.
    J Natl Cancer Inst. 2024;116:1598-1611.
    >> Share

    September 2024
  6. EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al
    Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.
    J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093.
    >> Share

    August 2024
  7. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    >> Share

    July 2024
  8. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
    Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
    J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
    >> Share

    June 2024
  9. DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al
    Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
    J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093.
    >> Share

    May 2024
  10. BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al
    Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor Antagonists.
    J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093.
    >> Share

    February 2024
  11. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
    >> Share

  12. LAO Y, Guan X, Wang J, Bai Y, et al
    RE: Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study.
    J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093.
    >> Share

    January 2024
  13. LEE KM, Nelson T, Bryant A, Teerlink C, et al
    Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
    J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
    >> Share

  14. WILKINSON S, Sowalsky AG
    Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
    J Natl Cancer Inst. 2024;116:12-14.
    >> Share

  15. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2024;116:167-169.
    >> Share

    December 2023
  16. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
    J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093.
    >> Share

    November 2023
  17. FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al
    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
    J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093.
    >> Share

  18. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    >> Share

    October 2023
  19. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    >> Share

  20. MA T, Jin L, Bai S, Liu Z, et al
    Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression.
    J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093.
    >> Share

    September 2023
  21. KENSLER KH, Johnson R, Morley F, Albrair M, et al
    Prostate Cancer Screening in African American Men: A Review of the Evidence.
    J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093.
    >> Share

  22. SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al
    Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
    J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093.
    >> Share

    August 2023
  23. DANIELS JP, Freedland SJ, Gresham G
    The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    J Natl Cancer Inst. 2023 Aug 16:djad140. doi: 10.1093.
    >> Share

  24. WOLINSKY H
    Re: Putting patients first to redefine prostate cancer classifications: Patients' viewpoints on redefining Grade Group 1.
    J Natl Cancer Inst. 2023 Aug 16:djad160. doi: 10.1093.
    >> Share

    July 2023
  25. YOO M, Nelson RE, Haaland B, Dougherty M, et al
    Cost-Effectiveness Analysis of seven treatments In Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public-Payer Perspective.
    J Natl Cancer Inst. 2023 Jul 12:djad135. doi: 10.1093.
    >> Share

  26. NYAME YA, Gore JL, Lin DW
    Putting patients first to redefine prostate cancer classifications.
    J Natl Cancer Inst. 2023 Jul 10:djad124. doi: 10.1093.
    >> Share

    June 2023
  27. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    >> Share

  28. LUYENDIJK M, Visser O, Blommestein HM, de Hingh IHJT, et al
    Changes in survival in de novo metastatic cancer in an era of new medicines.
    J Natl Cancer Inst. 2023;115:628-635.
    >> Share

  29. BERLIN A, Ramotar M, Santiago AT, Liu Z, et al
    The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
    J Natl Cancer Inst. 2023 Jun 7:djad108. doi: 10.1093.
    >> Share

    January 2023
  30. CHU CE, Leapman MS, Zhao S, Cowan JE, et al
    Prostate cancer disparities among American Indians/Alaskan Natives in the United States.
    J Natl Cancer Inst. 2023 Jan 11:djad002. doi: 10.1093.
    >> Share

  31. HAIMAN CA, Kote-Jarai Z, Darst BF, Conti DV, et al
    RE: Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2023 Jan 11:djad005. doi: 10.1093.
    >> Share

  32. HOULAHAN KE, Livingstone J, Fox NS, Kurganovs N, et al
    A polygenic two-hit hypothesis for prostate cancer.
    J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093.
    >> Share

    December 2022
  33. HU X, Lipscomb J, Jiang C, Graetz I, et al
    Vertical integration of oncologists and cancer outcomes and costs in metastatic Castration-Resistant prostate cancer.
    J Natl Cancer Inst. 2022 Dec 30:djac233. doi: 10.1093.
    >> Share

    November 2022

  34. Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
    J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
    >> Share

    October 2022
  35. PAGADALA MS, Lynch J, Karunamuni R, Alba PR, et al
    Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2022 Oct 28. pii: 6777270. doi: 10.1093.
    >> Share

  36. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    >> Share

    September 2022
  37. AWASTHI S, Grass GD, Torres-Roca J, Johnstone PAS, et al
    Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
    J Natl Cancer Inst. 2022 Sep 2. pii: 6687132. doi: 10.1093.
    >> Share

    July 2022
  38. TAKAHASHI T
    RE: Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Jul 26. pii: 6650145. doi: 10.1093.
    >> Share

    June 2022
  39. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    >> Share

    April 2022
  40. LAI LY, Oerline MK, Caram MEV, Tsao PA, et al
    Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568024. doi: 10.1093.
    >> Share

  41. KEATING NL
    Cardiovascular and Metabolic Diagnoses Associated with Novel Hormonal Agents for Prostate Cancer in Non-Trial Populations.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568021. doi: 10.1093.
    >> Share

  42. QIAO EM, Lynch JA, Lee KM, Kotha NV, et al
    Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    J Natl Cancer Inst. 2022;114:592-599.
    >> Share

    March 2022
  43. BORREGALES LD, DeMeo G, Gu X, Cheng E, et al
    Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Mar 28. pii: 6555003. doi: 10.1093.
    >> Share

    November 2021
  44. MARK M, von Moos R, Cathomas R, Stoffel S, et al
    RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Nov 29. pii: 6446038. doi: 10.1093.
    >> Share

    October 2021
  45. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    >> Share

    July 2021
  46. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    >> Share

  47. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    >> Share

  48. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    >> Share

    May 2021
  49. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    >> Share

  50. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    >> Share

  51. OLSSON H, Nordstrom T, Jaderling F, Egevad L, et al
    Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    J Natl Cancer Inst. 2021;113:632-640.
    >> Share

  52. BECKER DJ, Rude T, Walter D, Wang C, et al
    The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    J Natl Cancer Inst. 2021;113:626-631.
    >> Share

    April 2021
  53. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    >> Share

  54. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    >> Share

    November 2020
  55. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    >> Share

    October 2020
  56. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    >> Share

    September 2020
  57. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016